Investigation of the effect of brexpiprazole on acute or relapse schizophrenia using the positive and negative syndrome scale: an experimental report

Brexpiprazole (BPZ) is a novel antipsychotic drug in the category of serotonin-dopamine activity modulators (SDAMs). It expected to be effective treatment schizophrenia because its low side effects and ability reduce psychosis. However, clinical data Japan are still insufficient. We prescribed BPZ 41 schizophrenic patients; 9 dropped out 32 were retrospectively reviewed for psychiatric symptoms using positive negative syndrome scale (PANSS). The results showed that there was significant improvement total score, scale, general psychopathology all after 4 weeks. started 1 week 2 weeks scale. suggest not only acute phase, but also subacute phase. Further studies needed investigate efficacy by patient's characteristics as well sub-items PANSS.